This study examines the influence of pharmacological treatments on foot functionality in patients with rheumatoid
arthritis over a five-year period. A longitudinal analysis categorized patients into different treatment groups,
assessing their foot function using the Foot Function Index (FFI) at the start and end of the study. The groups
are based on their pharmacological treatment. Pharmacological treatment groups were categorized into: I
methotrexate (MTX), II MTX plus biological treatments (including all variables), III biological treatment alone, and
IV a miscellaneous group comprising patients with diverse treatments, including patients for whom various drugs
had failed or who had not achieved remission with pharmacological treatment. The study included 206 RA patients
with an average age of 58.32 years and a disease evolution of 15.28 years. The analysis of the FFI in total and across
its domains of pain, disability, and activity revealed significant differences only in the pain domain (p=0.011), with
a trend toward worsening over time observed in the other domains. Notably, MTX treatment showed improvement
in the pain domain (decreasing from 45.76 in 2018 to 40.43 in 2023). Findings suggest that while pharmacological
treatments are essential in managing rheumatoid arthritis, their impact on foot function is limited, with MTX
demonstrating the most significant benefit in terms of pain reduction
